I am no scientist but I really liked page 19when the retts experts said the following.
1.Dr Kaufman said the outcome of the trial is very encouraging.Safety the primary goal was achieved .The variety of improved symptoms suggests that trofinetide is a drug that targets underlying the disorder rather than a symptomatic medication.The results of the trial are particularly significant because of the relatively short duration of the trial.
2,Dr Percy said the trial in children support and strengthen the promising results obtained .
3.Steve kaminsky the chief science officer of rettsyndrome .org says the results are very exciting .The data suggests that trofinetide is having a positive change on a number of Rett syndrome issues.We at rettsyndrome are very proud to have supported this game changing study believing the best is yet to come.
I believe all these people will be at the fda meeting which is being held shortly .
NEU Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)